Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Combining finasteride and dutasteride may enhance hair regrowth by targeting different enzymes, with positive results reported. Minoxidil, both oral and topical, is also used to improve effectiveness.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

Finasteride is discussed for hair loss treatment, with opinions divided on its safety and effectiveness. Some consider natural remedies, but these may also affect hormones.

A user named "paulsac11" shares their success story of treating hair loss. They started with topical minoxidil, then switched to oral minoxidil and dutasteride. They also used a shampoo and conditioner from Keeps. After eight months of treatment, they have seen significant improvement in their hairline.